Walker confirmed that trial activities will resume as soon as possible. Novavax’s upcoming Phase III trial will evaluate the ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

Phase III trial results of the R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax's Matrix-M adjuvant, has confirmed high efficacy and ...

and allows companies to make and distribute a product during a public health emergency while the FDA continues to review a ...

Novavax’s COVID-19 vaccine could be added to the UK’s growing arsenal of shots against the disease after it showed 89.3% efficacy in a late-stage trial. The shot is the first to show efficacy ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

"Importantly, both studies confirmed efficacy against the variant strains," Stanley Erck, chief executive officer at Novavax, said. There are more than 113,000 reported cases of B.1.1.7 in the UK ...

NOVAVAX is recommended for adults 18 years ... the data gathered thus far was ”robust and met the EU criteria for efficacy, safety and quality.” When the vaccine studies were carried out ...

The Novavax vaccine is the only non-mRNA updated COVID vaccine that has been available in the U.S. The vaccine had a 90% efficacy in its clinical trial, performing almost as well as the mRNA ...